ATHE — Alterity Therapeutics Share Price
Last trade - 00:00- $23.75m
- $20.92m
- AU$0.27m
- 28
- 3
- 100
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.78 | ||
| Price to Tang. Book | 4.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 142.52 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -254.69% | ||
| Return on Equity | -155.77% | ||
| Operating Margin | -7630.34% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.02 | 0.02 | 0 | 0.02 | 0.27 | 4.84 | 2.3 | 19.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Directors
- Geoffrey Kempler NEC (66)
- David Stamler CEO (60)
- Kathryn Andrews CFO (54)
- Phillip Hains SEC
- Lawrence Gozlan NED (42)
- Peter Marks NID (65)
- Brian Meltzer NID (67)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 11th, 1997
- Public Since
- March 28th, 2000
- No. of Shareholders
- 5,552
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,320,336,118
- Address
- L 3 460 Bourke St, MELBOURNE, 3000
- Web
- https://alteritytherapeutics.com/
- Phone
- +61 393494906
- Contact
- Hannah Howlett
- Auditors
- PricewaterhouseCoopers
Upcoming Events for ATHE
Similar to ATHE
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 19:12 UTC, shares in Alterity Therapeutics are trading at $3.50. This share price information is delayed by 15 minutes.
Shares in Alterity Therapeutics last closed at $3.50 and the price had moved by +74.13% over the past 365 days. In terms of relative price strength the Alterity Therapeutics share price has outperformed the S&P500 Index by +63.73% over the past year.
The overall consensus recommendation for Alterity Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAlterity Therapeutics does not currently pay a dividend.
Alterity Therapeutics does not currently pay a dividend.
Alterity Therapeutics does not currently pay a dividend.
To buy shares in Alterity Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.50, shares in Alterity Therapeutics had a market capitalisation of $23.75m.
Here are the trading details for Alterity Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ATHE
Based on an overall assessment of its quality, value and momentum Alterity Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Alterity Therapeutics is $10.98. That is 213.59% above the last closing price of $3.50.
Analysts covering Alterity Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.81 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alterity Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +207.82%.
As of the last closing price of $3.50, shares in Alterity Therapeutics were trading +53.55% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alterity Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alterity Therapeutics' management team is headed by:
- Geoffrey Kempler - NEC
- David Stamler - CEO
- Kathryn Andrews - CFO
- Phillip Hains - SEC
- Lawrence Gozlan - NED
- Peter Marks - NID
- Brian Meltzer - NID